All In Biotech

NDA 017351 · Viatris

Cortifoam

Hydrocortisone Acetate · Rectal

Last checked: Nov 19, 2026Latest source record: Mar 1, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1982

Feb 12, 1982

Approved uses

1

Original approval plus efficacy supplements

Registered trials

753

149 Phase 3, 82 recruiting

FAERS reports

6,436

5,690 serious, 1,629 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 15, 2024.

INDICATIONS AND USAGE Cortifoam ® is indicated as adjunctive therapy in the topical treatment of ulcerative proctitis of the distal portion of the rectum in patients who cannot retain hydrocortisone or other corticosteroid enemas.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 12, 1982 Original approval · Type 3 - New Dosage Form
1 products under this application
  • CORTIFOAM · HYDROCORTISONE ACETATE 10% · AEROSOL, METERED, RECTAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Hydrocortisone" as an intervention, any sponsor and status, largest first.

All 753 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective2,443
  • fatigue2,181
  • pain2,148
  • abdominal discomfort2,096
  • rash2,070
  • systemic lupus erythematosus2,043
  • off label use2,003
  • alopecia1,931
  • condition aggravated1,907
  • swelling1,864
  • rheumatoid arthritis1,847
  • glossodynia1,823

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20048
200515
200654
200718
200814
200923
201027
201137
201283
201350
201466
201592
2016152
2017158
2018240
2019357
2020446
2021826
2022962
2023858
2024905
2025697
2026348

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cortifoam (Hydrocortisone Acetate)

2024 spending

$507K

Beneficiaries

434

821 claims

Per beneficiary

$1,168

$28.02 per unit

View as table
YearSpending
2020$10,096
2021$258,053
2022$411,577
2023$527,716
2024$507,098

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,629 on PubMed

Sponsor: Viatris

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.